Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 3/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | IL2 | P60568 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 4/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 3/20 | 0.40 |
| ▸ | CPA1 | P15085 | 2/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28813427 | 0.86 | FPR2 (0.52) | FPR2FOLH1ALBIL2MME | |
| SCHEMBL28813429 | 0.86 | FPR2 (0.52) | FPR2FOLH1ALBIL2MME | |
| SCHEMBL148423 | 0.84 | FOLH1 (0.55) | FOLH1ALDH1A1MMEACECPA1 | |
| SCHEMBL8414223 | 0.84 | FOLH1 (0.55) | FOLH1ALDH1A1MMEACECPA1 | |
| SCHEMBL497336 | 0.84 | MME (0.56) | FOLH1ALDH1A1MMEPSMB5MEP1B | |
| SCHEMBL73955 | 0.84 | MME (0.56) | FOLH1ALDH1A1MMEPSMB5MEP1B | |
| SCHEMBL11581853 | 0.84 | MME (0.56) | FOLH1ALDH1A1MMEPSMB5MEP1B | |
| SCHEMBL1097668 | 0.83 | FPR2 (0.52) | FPR2FOLH1ALDH1A1MMEMEP1B | |
| SCHEMBL1098155 | 0.83 | ALDH1A1 (0.62) | FOLH1ALDH1A1MMEACECPA1 | |
| SCHEMBL1097115 | 0.83 | ITGB1 (0.51) | ALDH1A1MMEPSMB5MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-20110245327-A1 | Oligonucleotide Analogues | EXIQON A/S (DK) | 2011-10-06 | — | — | US | disclosed |
| EP-2341058-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-2341057-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245327-A1 | Oligonucleotide Analogues | POLRMT, POLM, POLN | FPR2 3091/4885FOLH1 975/4885ALDH1A1 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.